REX Shares Launches REX Peptide ETF (PEPT)

For best results when printing this announcement, please click on link below: REX Shares Launches REX Peptide ETF (PEPT) New thematic ETF targets the full peptide value chain: the drug developers, manufacturers, delivery specialists, and consumer brands behind today’s GLP-1 treatments and the pipeline forming beyond obesity, in one globally diversified trade. REX Shares (“REX”), a leading innovator in alternative ETFs, today announced the launch of the REX Peptide ETF (Ticker: PEPT), a thematic ETF built to own the peptide economy end to end.

PEPT holds the companies that develop, manufacture, deliver, and commercialize peptide-based products, expanding investor exposure beyond the two drugmakers that dominate today’s GLP-1 market. It is REX’s third thematic ETF, following the REX Drone ETF (DRNZ) and the REX AI Chipmaking ETF (CHIP). Peptides are the body’s own signaling molecules, re-engineered into precise, scalable medicines. They are the technology behind today’s GLP-1 treatments and a growing pipeline of therapies well beyond obesity, spanning metabolic disease, cardiovascular indications, oncology, and rare disease.

Most portfolios hold peptide exposure only through Eli Lilly and Novo Nordisk. In addition to those two names, PEPT owns the developers, manufacturers, and platforms behind them. Wherever the next generation of peptide treatment leads, it still has to be commercialized, manufactured, and delivered, and those are the parts of the chain PEPT touches. The launch comes early in the adoption curve.

S. adults taking a GLP-1 for weight loss has risen from 3% in 2024 to 11% in 2026(2). P. Morgan Global Research forecasts the global incretin market, which includes GLP-1s, reaching $200 billion by 2030(1), and Morgan Stanley Research expects the market for GLP-1 treatments of obesity and type 2 diabetes to more than double from $79 billion in 2025 to $190 billion by 2035(3).

Supply is now the constraint: demand for peptide manufacturing is outrunning capacity, and PEPT owns the manufacturers building it. “Investors have spent three years expressing the GLP-1 trade through two stocks. The companies that develop, make, and deliver peptides are where the next phase of growth has to run through,” said Greg King, CEO and Founder of REX Shares. “Whichever peptide wins the next indication, it still gets manufactured and delivered by the same supply chain.

” The ETF is based on the VettaFi Peptide Index, which tracks global companies positioned to advance the development, manufacturing, and commercial adoption of peptide-based products. The index spans four segments: therapeutics and medicine, manufacturing and medical devices, nutraceuticals and supplements, and cosmeceuticals and skincare. Constituents must have a minimum market capitalization of $100 million and a three-month average daily traded value of at least $1 million.

The methodology allocates at least 80% of index weight to pure-play companies deriving at least half of their revenue or research and development activity from peptides, with constituent caps limiting concentration(4). 26, the index holds 36 constituents. S. S.

1%. 65%. For full fund information, holdings, and risk disclosures, visit Sources 1. P.

Morgan Global Research, “How demand for (and supply of) weight loss drugs is playing out in 2026,” February 2026. 2. , GLP-1 Usage Reaches New High,” Gallup National Health and Well-Being Index, July 7, 2026 (updated September 8, 2026). 3.

Morgan Stanley Research, “Obesity Drugs Are Scaling Fast,” April 2026. 4. VettaFi, Peptide Index methodology; REX ETF Trust, REX Peptide ETF prospectus dated October 10, 2026. About REX Shares REX Shares offers a suite of exchange-traded products built for both active traders and long-term investors, spanning income, crypto, thematic, and leveraged strategies.

Whether making short-term trades, generating income from volatility, or investing in digital assets and emerging themes like drones, AI chipmaking, and peptides, REX empowers investors to act on strong market views. Important Information The Fund is new and has no operating history, and the Index launched on September 24, 2026. No performance is presented in this communication. The Index's exposure to peptides may be indirect.

Up to 20% of the Index may be allocated to companies that derive less than half of their revenue or research and development activity from peptide-related operations, and constituents may derive significant revenues from broader pharmaceutical, health care, or consumer businesses. The Index's eligibility screen is a segment and revenue screen, not a guarantee of peptide-related revenue. An investment in the Fund entails risk, including possible loss of principal. The Fund is not a complete investment program.

It is important that investors review the risks below and the risks described in the prospectus, and understand them, before making an investment in the fund. Investors should consider the investment objectives, risk, charges, and expenses carefully before investing. com. Read the prospectus and summary prospectus carefully before investing.

Important Risks Peptide Industry Risk. Companies involved in the development, manufacturing, and commercialization of peptide-based products face intense competition, lengthy and uncertain regulatory approval processes, clinical trial failures, patent expirations, pricing and reimbursement pressure, and rapid product obsolescence. Their share prices may be more volatile than the broader market. Biotechnology, Pharmaceutical, and Health Care Sector Risk.

The Fund invests in companies in the biotechnology, pharmaceutical, and health care sectors. These businesses are heavily dependent on government approvals and regulation, patent protection, and the outcome of clinical trials, and can be materially affected by changes in health care policy, drug pricing legislation, supply chain disruption, manufacturing capacity constraints, and product liability claims. Concentration Risk and Non-Diversification Risk. The Fund concentrates its investments in an industry or group of industries, and as a non-diversified fund it may invest a greater portion of its assets in the securities of a single issuer.

Both increase the effect that any single holding or industry development has on the Fund's value. Foreign Securities, Currency, Depositary Receipts, Europe and Asia Risk. The Fund invests significantly in securities of non-US issuers, directly and through depositary receipts. Foreign investments involve risks not typically associated with US investments, including currency fluctuation, different regulatory and accounting standards, less liquidity, higher transaction costs, and political and economic developments specific to a country or region.

The Index may have significant exposure to Europe and Asia. New Fund, New Index, Index Provider, Passive Investment and Non-Correlation Risk. The Fund is recently organized and has no operating history. The Index is newly created and has a limited history.

The Fund is not actively managed and relies on the Index Provider's methodology and data; errors in index construction or calculation may not be identified or corrected promptly. The Fund's return may not match the Index's return. Equity, Large, Mid and Small Capitalization, Liquidity, Volatility, Trading Issues, Premium/Discount, Costs of Buying and Selling Fund Shares, Authorized Participant and Operational Risk. Equity values rise and fall.

Smaller companies may be more volatile and less liquid than larger companies. Shares may trade at a premium or discount to net asset value, trading may be halted, and the Fund relies on a limited number of authorized participants and market makers. Buying and selling shares involves brokerage and other costs. 65%.

The Adviser pays all Fund expenses excluding the management fee, interest, taxes, acquired fund fees and expenses, and brokerage commissions. See the prospectus for the full fee table, the investment objective, and complete risk disclosures. The Fund is a series of REX ETF Trust. The Fund's investment adviser is REX Advisers, LLC.

The VettaFi Peptide Index is a service mark of VettaFi LLC and has been licensed for use by REX Shares, LLC and the REX Peptide ETF. The REX Peptide ETF is not sponsored, endorsed, sold or promoted by VettaFi LLC and VettaFi LLC makes no representation regarding the advisability of investing in the REX Peptide ETF. Distributor: Foreside Fund Services, LLC, member FINRA, not affiliated with REX Shares or the Fund’s investment advisor. com)